Announcement on Voluntary Disclosure of Receipt of Drug Registration Certificate for Ponatinib Tablets
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Receipt of Drug Registration Certificate for Ponatinib Tablets
Filed with SSE · Stock code 688513 · · 2 pages · Chinese
Summary by 6ix AI
Chengdu Easton Biopharmaceuticals Co., Ltd. announced the voluntary disclosure of receiving a drug registration certificate for Ponatinib Tablets.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Release
Chengdu Easton Biopharmaceuticals Co., Ltd. on 6ix
Story so far
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Vitamin K1 Injection
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
- Announcement on Closure of Certain Special Accounts for Raised Funds
Earlier from Chengdu Easton Biopharmaceuticals
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Vitamin K1 Injection
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
- Announcement on Closure of Certain Special Accounts for Raised Funds
- Announcement on Voluntary Disclosure of Progress of Phase I Clinical Trials for EP-0226 Tablets
- Announcement on Resolutions of the 16th Meeting of the 4th Board of Directors
Later from Chengdu Easton Biopharmaceuticals
All Chengdu Easton Biopharmaceuticals news releasesFollow Chengdu Easton Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Easton Biopharmaceuticals